1Introduction: What Is JBSNF-000088?
At a Glance
JBSNF-000088 (6-methoxynicotinamide) is a small-molecule analog of nicotinamide (NA) that functions as a potent, orally bioavailable inhibitor of nicotinamide N-methyltransferase (NNMT) — a cytosolic enzyme whose elevated expression in adipose tissue and liver is strongly associated with obesity, insulin resistance, and type 2 diabetes.
Discovered through high-throughput screening and characterized in a landmark 2018 study by Kannt et al. (published in Scientific Reports), JBSNF-000088 was the first small-molecule NNMT inhibitor to demonstrate pharmacological proof-of-concept in preclinical animal models of metabolic disease. Its co-crystal structure with human NNMT (PDB: 5YJF) revealed that it acts as a slow-turnover substrate analog, providing unparalleled structural insight into the inhibition mechanism.
Supplied as a ≥98% HPLC-verified powder, JBSNF-000088 is intended exclusively for in vitro and animal-model laboratory research. It is not approved by the FDA or any regulatory authority for human consumption, diagnosis, or therapeutic use.
To understand why JBSNF-000088 has become a sought-after research tool, it is important to grasp the role of its target enzyme. NNMT catalyzes the N-methylation of nicotinamide using S-adenosyl-L-methionine (SAM) as the methyl donor, producing 1-methyl-nicotinamide (MNA) and S-adenosyl-L-homocysteine (SAH). When NNMT is overexpressed — as occurs in obese adipose tissue — it simultaneously depletes nicotinamide (a key NAD+ precursor) and SAM (the universal methyl donor). This dual depletion disrupts cellular energy metabolism and epigenetic regulation, contributing to metabolic dysfunction.
JBSNF-000088 blocks this process by occupying the nicotinamide-binding pocket of NNMT, thereby preserving intracellular nicotinamide and SAM levels. The result is a restoration of NAD+ salvage pathway activity and methyl-donor homeostasis — effects that translate into measurable improvements in body weight, glucose tolerance, and insulin sensitivity in preclinical models.
2Product Parameters: Physicochemical Data
The following specifications define the identity, purity, and physical characteristics of our JBSNF-000088 powder. Each batch is accompanied by a Certificate of Analysis (COA) documenting HPLC purity, identity confirmation by NMR and mass spectrometry, and residual solvent screening.
| Technical Specifications — JBSNF-000088 | |
|---|---|
| Product Name | JBSNF-000088 (6-Methoxynicotinamide) |
| CAS Number | 7150-23-4 |
| Synonyms | 6-Methoxypyridine-3-carboxamide; NSC 70628 |
| Molecular Formula | C7H8N2O2 |
| Molecular Weight | 152.15 g/mol |
| SMILES | COC1=NC=C(C=C1)C(=O)N |
| InChI Key | KXDSMFBEVSJYRF-UHFFFAOYSA-N |
| Chemical Class | Nicotinamide analog (small molecule, non-peptide) |
| Appearance | Off-white to white solid (crystalline powder) |
| Purity | ≥98% (HPLC) |
| Charge State | Neutral (non-ionic at physiological pH) |
| Solubility (DMSO) | 30 mg/mL (197.17 mM) |
| Solubility (Ethanol) | 6–7 mg/mL |
| Solubility (Water) | ~2 mg/mL (practically insoluble) |
| UV λmax | 240 nm, 273 nm |
| Storage Conditions | −20°C, desiccated, protected from light |
| Shelf Life (Powder) | 36 months when stored at −20°C as directed |
| Shelf Life (In Solvent) | 12 months at −80°C; 1 month at −20°C |
| Intended Use | Laboratory research only (in vitro / animal models) |
Why the neutral charge matters: Unlike cationic NNMT inhibitors (e.g., quinolinium-based compounds), JBSNF-000088 is a neutral, drug-like molecule with a low molecular weight of 152.15 g/mol. This favorable physicochemical profile supports passive membrane permeability, oral absorption, and broad tissue distribution — properties validated by pharmacokinetic studies showing ~40% oral bioavailability in mice.
3Product Advantages: Why Choose JBSNF-000088?
As the NNMT inhibitor research landscape expands, researchers face an increasing number of tool compounds. JBSNF-000088 stands out for several scientifically and practically significant reasons — from its structural elegance to its proven in vivo performance.
3.1 Co-Crystal-Validated Mechanism (Structural Certainty)
JBSNF-000088 is one of the few NNMT inhibitors with a publicly deposited co-crystal structure (PDB: 5YJF, resolution 2.49 Å). X-ray diffraction analysis revealed that the N-methylated product of JBSNF-000088 occupies the nicotinamide-binding pocket of human NNMT, confirming it as a slow-turnover substrate analog. This structural evidence provides researchers with confidence in the compound's on-target mechanism and enables rational structure-based drug design follow-up studies — something not available for all NNMT inhibitors in the field.
(6-Methoxy-NA) → NNMT Active Site
(nicotinamide pocket) ⊛ NNMT Inhibited
(NAD+ preserved) + SAM ↑
(Methyl donor restored) → Improved Insulin Sensitivity
& Glucose Tolerance
Mechanism: JBSNF-000088 occupies the NNMT substrate pocket, preventing nicotinamide methylation and preserving both NAD+ precursors and methyl-donor pools.
3.2 Orally Bioavailable with Favorable Pharmacokinetics
Pharmacokinetic profiling in C57BL/6 mice demonstrated that JBSNF-000088 achieves rapid oral absorption (Tmax = 0.5 h) with a peak plasma concentration (Cmax) of 3,568 ng/mL at 10 mg/kg oral gavage. The oral bioavailability was approximately 40%, with low plasma clearance (21 mL/min·kg) and a moderate volume of distribution (0.7 L/kg). These drug-like properties make JBSNF-000088 particularly well-suited for chronic oral dosing studies in metabolic disease models.
| Pharmacokinetic Profile (Mouse) | ||
|---|---|---|
| Parameter | IV (1 mg/kg) | Oral (10 mg/kg) |
| Cmax | — | 3,568 ng/mL |
| Tmax | — | 0.5 h |
| Plasma Half-life (t½) | 0.5 h | 0.4 h |
| Clearance (CL) | 21 mL/min·kg | — |
| Vd,ss | 0.7 L/kg | — |
| Oral Bioavailability (F) | ~40% | |
3.3 Head-to-Head: JBSNF-000088 vs. 5-Amino-1MQ
Both JBSNF-000088 and 5-Amino-1MQ target NNMT, but they differ fundamentally in chemical scaffold, charge, and research utility. Understanding these differences helps researchers select the right tool for their experimental design.
| Parameter | JBSNF-000088 | 5-Amino-1MQ |
|---|---|---|
| Chemical Scaffold | Nicotinamide analog | Quinolinium derivative |
| CAS Number | 7150-23-4 | 42464-96-0 |
| Molecular Weight | 152.15 g/mol (lower) | ~286 g/mol (iodide salt) |
| Charge State | Neutral (drug-like) | Permanent cation (quaternary N) |
| IC50 (human NNMT) | 1.8 µM | ~1.2 µM (slightly more potent) |
| Oral Bioavailability | ~40% (PK-validated) | Not formally reported |
| Co-Crystal Structure | Yes (PDB: 5YJF, 2.49 Å) | No public co-crystal |
| Originating Lab | Sanofi / NovAliX (Kannt 2018) | UTMB (Neelakantan 2018) |
| Water Solubility | ~2 mg/mL (low) | ~10–15 mg/mL (high) |
| DIO Mouse Efficacy | Body weight ↓, glucose ↓, insulin sens. ↑ | Body weight ↓, WAT mass ↓, cholesterol ↓ |
| Knockout Specificity Confirmed | Yes (NNMT-KO mice) | Not reported |
| Drug-Likeness (Lipinski) | Fully compliant | Cationic; may violate permeability |
Bottom line for researchers: Choose 5-Amino-1MQ when you need maximum aqueous solubility and slightly higher enzymatic potency. Choose JBSNF-000088 when you need a neutral, drug-like molecule with validated oral PK, a co-crystal structure for structural biology work, and genetically confirmed on-target specificity (NNMT knockout validation). Many research groups use both compounds as complementary tools.
3.4 Genetic Validation of Specificity
A critical advantage of JBSNF-000088 is that its metabolic effects were absent in NNMT-knockout mice fed a high-fat diet. This genetic control experiment confirms that the observed reductions in body weight, blood glucose, and triglycerides are specifically mediated through NNMT inhibition — not through off-target pharmacology. For researchers publishing in high-impact journals, this level of target specificity validation is invaluable and frequently requested by reviewers.
4Application Scenarios: Who Uses JBSNF-000088?
JBSNF-000088 is used across a range of research domains where NNMT activity is implicated. The following scenarios represent the most common and emerging applications for this compound.
Obesity & Type 2 Diabetes Research
Pharmacology labs studying NNMT as a therapeutic target for diet-induced obesity, insulin resistance, and glucose intolerance. JBSNF-000088 serves as a positive control compound in DIO mouse studies and phenotypic screening assays.
Enzymology & Crystallography
Structural biologists leveraging the published co-crystal structure (PDB: 5YJF) for structure-based drug design, molecular docking studies, and SAR campaigns to develop next-generation NNMT inhibitors.
SAM/Methylation Pathway Research
Researchers investigating how NNMT-mediated SAM depletion affects DNA and histone methylation patterns, particularly in adipogenesis, hepatic steatosis, and metabolic epigenetics.
Oncology & Tumor Metabolism
Groups studying NNMT overexpression in cancers (pancreatic, colorectal, gastric) and its role in epigenetic dysregulation within the tumor microenvironment. JBSNF-000088 is used as a tool to restore SAM availability in vitro.
Nicotinamide / NAD+ Metabolism
Labs exploring the intersection of NNMT activity and NAD+ homeostasis — including cross-talk with NAD+ precursors (NMN, NR) and sirtuin signaling pathways in aging and metabolic research.
Phenotypic & Target-Based Screening
Pharmaceutical and biotech teams using JBSNF-000088 as a reference inhibitor in HTS assay validation, hit confirmation, and benchmark potency comparisons during lead optimization campaigns.
NAD+ Booster Interaction Studies
Research groups investigating the cross-talk between NNMT inhibition and exogenous NAD+ precursors (NMN, NR, nicotinamide riboside). JBSNF-000088 is used to probe whether blocking nicotinamide methylation enhances or synergizes with NAD+ boosting strategies, informing next-generation metabolic supplement design.
4.1 Recommended Assay Concentrations
Based on published IC50 values and in vivo dosing protocols, the following concentration ranges are commonly used as starting points. Researchers should always optimize for their specific assay conditions and cell/animal models.
| Recommended Working Conditions | |
|---|---|
| Cell-free NNMT enzyme assay | 0.1–50 µM (IC50 ≈ 1.8 µM hNNMT) |
| U2OS cell-based assay | 0.1–30 µM (IC50 ≈ 1.6 µM) |
| 3T3-L1 adipocyte assay | 0.5–50 µM (IC50 ≈ 6.3 µM) |
| In vivo oral dosing (mice) | 50 mg/kg, BID, oral gavage (4-week DIO study) |
| Stock solution preparation | DMSO at 10–30 mg/mL; aliquot and store at −80°C |
5Packaging, Storage & Shipping Regulations
For research procurement teams, understanding the packaging, storage, and shipping requirements of JBSNF-000088 is essential. This section addresses the most common logistical questions — including whether the compound is a controlled or prohibited substance, how it should be stored, and what transport conditions apply.
Packaging
Sealed amber glass vials with moisture-barrier seals; nitrogen-flushed. Available in 25 mg, 100 mg, 250 mg, 500 mg, 1 g, and bulk quantities.
Storage
Powder: −20°C, desiccated, protected from light (36-month shelf life). In-solution stocks: −80°C for 12 months.
Shipping
Room-temperature ambient shipping for powder form. Cold-chain (dry ice) optional for pre-dissolved stocks. UN hazard class: non-regulated.
5.1 Is JBSNF-000088 a Controlled or Prohibited Substance?
No. JBSNF-000088 (CAS 7150-23-4) is not listed on any international drug control schedule. It is not a narcotic, psychotropic, precursor, or scheduled substance under the UN Convention on Psychotropic Substances or the US Controlled Substances Act. It is classified as a research chemical / fine chemical and ships under standard chemical shipping classifications.
WADA Note: While JBSNF-000088 is not a controlled substance, it would fall under S0 (Non-Approved Substances) on the WADA Prohibited List if used by athletes subject to anti-doping testing. Researchers and institutions are responsible for ensuring compliance with all applicable institutional and regulatory policies.
5.2 Shipping Conditions & Transport Requirements
- Powder form: Ships at ambient temperature (room temperature) in continental regions. No cold-chain required for standard transit times of ≤7 days. For tropical-climate destinations or extended transit, insulated packaging with gel packs is recommended.
- Pre-dissolved DMSO stocks: Ship on dry ice (−78°C) to prevent degradation. Dry ice shipments require UN 1845 dangerous goods documentation.
- UN Hazard Classification: Non-regulated chemical (not classified as dangerous goods under IATA / IMDG / ADR for powder quantities <1 kg). SDS available on request.
- Customs / Import: HS code typically 29333990 (nicotinamide derivatives). Import permits are generally not required for research-scale quantities, but buyers should verify with their national customs authority and institutional biosafety office.
- Documentation included: Certificate of Analysis (COA), Safety Data Sheet (SDS), packing list, and commercial invoice with accurate HS classification.
5.3 Storage & Shelf Life Summary
| Storage Conditions & Stability | ||
|---|---|---|
| Form | Temperature | Stability |
| Solid powder (sealed, desiccated) | −20°C | 36 months |
| Stock solution (DMSO or DMF) | −80°C | 12 months |
| Stock solution (DMSO or DMF) | −20°C | 1 month |
| Working dilutions (aqueous buffer) | 4°C | Use within 24 hours (prepare fresh) |
To maintain maximum potency, avoid repeated freeze-thaw cycles of stock solutions. We recommend aliquoting DMSO stock into single-use volumes upon first dissolution. The powder should be allowed to equilibrate to room temperature before opening the container to prevent moisture condensation, especially in humid environments.
6Frequently Asked Questions (FAQ)
Below we address the most common questions researchers and procurement teams ask about JBSNF-000088 — covering mechanism, handling, comparison, logistics, and regulatory status.
Q: What is the difference between JBSNF-000088 and 6-Methoxynicotinamide?
They are the same compound. "JBSNF-000088" is the internal code number assigned during the high-throughput screening campaign at Sanofi/NovAliX that led to its discovery. "6-Methoxynicotinamide" is the systematic chemical name, and "NSC 70628" is an older NSC registry identifier. All three names refer to CAS 7150-23-4.
Q: How does JBSNF-000088 inhibit NNMT?
JBSNF-000088 is a nicotinamide analog that enters the NNMT active site and acts as a slow-turnover substrate. The enzyme attempts to methylate it, but the N-methylated product remains tightly bound in the active site (confirmed by co-crystal structure PDB: 5YJF), effectively blocking the enzyme. This competitive, substrate-analog mechanism preserves both nicotinamide and SAM pools within the cell.
Q: What is the IC50 of JBSNF-000088 against NNMT?
The reported IC50 values are: 1.8 µM for human NNMT, 2.8 µM for monkey NNMT, and 5.0 µM for mouse NNMT in cell-free assays. In cellular assays, the IC50 is 1.6 µM in U2OS cells and 6.3 µM in differentiated 3T3-L1 adipocytes.
Q: Was JBSNF-000088's efficacy confirmed in NNMT-knockout mice?
Yes. In a critical specificity control, JBSNF-000088 produced no metabolic effects in NNMT-knockout mice on a high-fat diet, confirming that its weight-loss and glucose-lowering effects are specifically mediated through NNMT inhibition rather than off-target activity. This genetic validation is a major strength of the compound's published data package.
Q: Is JBSNF-000088 the same as 5-Amino-1MQ?
No. While both are NNMT inhibitors, they have different chemical scaffolds: JBSNF-000088 is a neutral nicotinamide analog (MW 152.15, CAS 7150-23-4) with validated oral PK and a co-crystal structure, whereas 5-Amino-1MQ is a quinolinium-based cation (CAS 42464-96-0) with slightly higher potency but different physicochemical and pharmacokinetic properties. They are complementary research tools.
Q: Is JBSNF-000088 soluble in water?
JBSNF-000088 has low aqueous solubility (~2 mg/mL). It is best dissolved in DMSO (30 mg/mL / 197 mM) or ethanol (6–7 mg/mL) for stock solutions. For in vivo oral gavage, a CMC-Na suspension formulation is commonly used. For in vitro assays, DMSO stock diluted into aqueous buffer (final DMSO ≤0.1–0.5%) is recommended.
Q: Is JBSNF-000088 a controlled substance? Can it be shipped internationally?
No, it is not a controlled substance. JBSNF-000088 is not listed on any narcotics, psychotropic, or precursor control schedule. It is classified as a non-regulated research chemical and ships under standard chemical shipping classifications. International shipping is available with proper customs documentation (HS code 29333990). Always check with your institutional and national import regulations.
Q: What is the recommended storage condition and shelf life?
Store the powder at −20°C, desiccated and protected from light. Under these conditions, the shelf life is 36 months. DMSO stock solutions should be aliquoted and stored at −80°C (stable for 12 months) or −20°C (stable for 1 month). Avoid repeated freeze-thaw cycles.
Q: What dosing protocol was used in the published preclinical study?
In the Kannt et al. (2018) DIO mouse study, JBSNF-000088 was administered at 50 mg/kg orally, twice daily (BID), for 4 weeks. This resulted in significant body weight reduction, improved insulin sensitivity, and normalized glucose tolerance. Pharmacokinetic studies used 1 mg/kg IV and 10 mg/kg oral single doses.
Q: Can JBSNF-000088 be used in human clinical trials?
No. JBSNF-000088 has not been approved by the FDA, EMA, or any regulatory authority for human use. It is a research chemical intended exclusively for in vitro and animal-model laboratory research. Any clinical development would require extensive additional preclinical toxicology, IND application, and regulatory approval.
Q: Do you provide bulk pricing and custom packaging?
Yes. We offer tiered volume pricing for orders from multi-gram to kilogram scale. Custom packaging configurations, dedicated batch reservation, net-30 payment terms for institutional accounts, and comprehensive technical support are available. Contact our procurement team for a customized quote.
Q: What quality documentation accompanies each order?
Every shipment includes a Certificate of Analysis (COA) documenting HPLC purity (≥98%), identity confirmation (NMR and LC-MS), and residual solvent content. A Safety Data Sheet (SDS) is available upon request. Additional analytical data packs (GC-MS, TGA, KF titration) can be provided for GMP-adjacent research applications.
7Summary & Procurement
JBSNF-000088 (6-methoxynicotinamide) occupies a unique position in the NNMT inhibitor landscape. As the first small-molecule NNMT inhibitor with pharmacological proof-of-concept in preclinical metabolic disease models, it offers researchers a combination of features that few competing compounds can match:
- Structural certainty: Co-crystal structure (PDB: 5YJF) confirming on-target, substrate-analog mechanism
- Genetic validation: Efficacy absent in NNMT-knockout mice, ruling out off-target effects
- Drug-like properties: Neutral, low-MW molecule with ~40% oral bioavailability and favorable PK
- Comprehensive efficacy data: Body weight reduction, glucose normalization, insulin sensitization, and triglyceride lowering across three mouse models (DIO, ob/ob, db/db)
- Logistical simplicity: Non-controlled research chemical, ambient shipping, 36-month shelf life
Whether you are conducting enzymology studies, phenotypic screening, in vivo pharmacology, or structure-based drug design, JBSNF-000088 provides a well-characterized, publication-ready tool compound backed by peer-reviewed data in Scientific Reports. Its combination of genetic specificity validation, structural biology support, and drug-like pharmacokinetic properties makes it an ideal reference compound for any laboratory building an NNMT-focused research program.
Purity Verification
Every batch verified ≥98% by HPLC, with identity confirmed by NMR and LC-MS. Full COA provided with each shipment.
Global Shipping
Non-controlled research chemical. Ambient shipping for powder; cold-chain available for solutions. Customs documentation included.
Flexible Packaging
From 25 mg evaluation samples to kilogram-scale bulk orders. Custom aliquoting and dedicated batch reservation available.
Technical Support
Dedicated technical liaison for formulation guidance, assay optimization, and regulatory documentation requests.
Ready to Source JBSNF-000088 for Your Research?
Get ≥98% HPLC-verified JBSNF-000088 powder with full COA documentation, competitive pricing, and reliable global shipping.